STK11 and non-small cell lung carcinoma: Additionally, a retrospective analysis of the Keynote-042 trial, which evaluated pembrolizumab vs. platinum-based chemotherapy in NSCLC in the first-line setting, revealed comparable response rates between STK11 mutated and STK11 wild-type tumors [5].